|
000
| 02310cam 2200301za 4500 |
|---|
| 001 | 9.838719 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107151438 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 170623s2017 oncd ob f000 0 eng d |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aD2-526/2017E-PDF |
|---|
| 245 | 00|aSurgeon General report on mefloquine |h[electronic resource]. |
|---|
| 246 | 17|aSurgeon General task force report on mefloquine |
|---|
| 260 | |a[Ottawa] : |b[National Defence], |c[2017] |
|---|
| 300 | |a66 p. : |bcol. chart |
|---|
| 500 | |aIssued also in French under title: Rapport du médecin général sur la méfloquine. |
|---|
| 500 | |aCover title. |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 520 | |a“The Canadian Armed Forces (CAF) approach to malaria prevention, including use of malaria medication (called malaria chemoprophylaxis (MCP)), is consistent with the Canadian clinical practice guidelines (CPG) on malaria prevention and treatment. In most areas where the most dangerous form of malaria occurs (Plasmodium falciparum), the Canadian CPG and the CAF recommend that travelers use one of three options for MCP: mefloquine, atovaquone-proguanil (AP) (brand name Malarone), or doxycycline. Within the CAF and with respect to these options, the current policy is that the individual member, after suitable discussion with their health care provider, can choose his/her preferred agent from among those that are deemed medically suitable. The continued use of mefloquine as a MCP option in the CAF has recently received significant scrutiny. Given the concerns that have been raised about mefloquine, the Canadian Armed Forces Chief of Defence Staff (CDS) instructed the Surgeon General (SG) to critically analyze the body of knowledge regarding mefloquine, and to undertake a review of the CAF experience with the medication. This report is the SG response to this tasking"--Introd., p. 1, 2. |
|---|
| 692 | 07|2gccst|aMilitary personnel |
|---|
| 692 | 07|2gccst|aDrugs |
|---|
| 692 | 07|2gccst|aHealth impact |
|---|
| 710 | 1 |aCanada. |bDepartment of National Defence. |
|---|
| 710 | 1 |aCanada.|bSurgeon General Branch. |
|---|
| 775 | 08|tRapport du médecin général sur la méfloquine |w(CaOODSP)9.838720 |
|---|
| 856 | 40|qPDF|s984 KB|uhttps://publications.gc.ca/collections/collection_2017/mdn-dnd/D2-526-2017-eng.pdf |
|---|